OINDPnews


H&T Presspart banner

Business

Bryn Pharma raises $11 million for continued development of its epinephrine nasal spray

Bryn Pharma said that it has raised $11 million in an extension of the financing that raised over $17 million in October 2019 to fund activities related to its BRYN-NDS1C epinephrine nasal spray candidate, which is delivered via Aptar Pharma's Bidose nasal device. According to Bryn, proceeds from this financing will be used for continued development of BRYN-NDS1C, as … [Read more...] about Bryn Pharma raises $11 million for continued development of its epinephrine nasal spray

United Therapeutics gets new patent for Tyvaso, adds to patent infringement claims against Liquidia

United Therapeutics announced that it has been issued a new US patent covering Tyvaso treprostinil inhalation solution for the treatment of pulmonary arterial hypertension and that it has subsequently amended its recently filed suit against Liquidia Technologies to include infringement of the new patent. The patent infringement suit initially referenced two US … [Read more...] about United Therapeutics gets new patent for Tyvaso, adds to patent infringement claims against Liquidia

Janssen announces launch of Spravato esketamine nasal spray in Canada

Health Canada has issued a Notice of Compliance for Janssen Pharmaceutical's Spravato esketamine nasal spray for the treatment of major depressive disorder, and the product is now available to Canadian patients, the company said. Spravato is meant to be used under direct supervision of a healthcare professional, and in combination with an oral antidepressant, when … [Read more...] about Janssen announces launch of Spravato esketamine nasal spray in Canada

Verona Pharma raises approximately $200 million for Phase 3 development of nebulized ensifentrine

Verona Pharma announced that it has raised approximately $200 million in a private placement, with net proceeds of ~$183 million to be used for Phase 3 development of nebulized ensifentrine for the treatment of COPD. The company said that the Phase 3 ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) program is expected to begin later this year. In … [Read more...] about Verona Pharma raises approximately $200 million for Phase 3 development of nebulized ensifentrine

ARS Pharmaceuticals gets second US patent for its epinephrine nasal spray

The United States Patent and Trademark Office has issued US Patent No. 10682414, titled, "Intranasal epinephrine formulations and methods for the treatment of disease," to ARS Pharmaceuticals, the company said. The patent covers the use of low dose (0.1 to 2.4 mg) intranasal epinephrine for for the treatment of anaphylaxis. The patent covers any low-dose … [Read more...] about ARS Pharmaceuticals gets second US patent for its epinephrine nasal spray

Optinose partners with Kaleo for promotion of Xhance intranasal fluticasone

Optinose announced that it has signed an agreement with Kaleo for co-promotion of Optinose's Xhance fluticasone propionate nasal spray for the treatment of nasal polyps. Xhance was approved by the FDA for that indication in September 2017. The agreement calls for Kaleo to promote the nasal spray to a group of almost 6,000 healthcare providers in the US.   Optinose … [Read more...] about Optinose partners with Kaleo for promotion of Xhance intranasal fluticasone